Open AccessSerologic and cellular assays to monitor therapy with murine monoclonal antibodies
Author(s) -
Shawler Daniel L.,
McCallister Tammy J.,
Sobol Robert E.,
Dillman Robert O.
Publication year - 1987
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.1860010207
Subject(s) - monoclonal antibody , immunofluorescence , immunohistochemistry , antibody , microbiology and biotechnology , antigen , hybridoma technology , monoclonal , immunoassay , in vivo , primary and secondary antibodies , serology , biology , immunology
The emergence of new therapeutic modalities frequently requires development of relevant laboratory assays. This is especially true for the clinical uses of newly developed reagents such as murine monoclonal antibodies. We have described immunofluorescence, immunohistochemical, and enzyme‐linked immunosorbent assays (ELISA) for monitoring anticancer therapy with monoclonal antibodies. Immunofluorescence assays performed on single cell suspensions and immunohistochemical assays performed on freshly frozen biopsy tissue have confirmed tissue reactivity of the monoclonal antibody prior to infusion and have been used to measure in vivo antibody binding to target cells as well as antigenic modulation during therapy. An ELISA has been used to measure the serum concentrations of monoclonal antibodies; another ELISA has been used to detect the presence of human antibodies reactive with murine monoclonal antibody. These reproducible assays can be performed with commercially available reagents and provide an important data base for making clinical decisions concerning therapy with monoclonal antibodies.